WO2004098491A3 - METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES - Google Patents

METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES Download PDF

Info

Publication number
WO2004098491A3
WO2004098491A3 PCT/US2003/034523 US0334523W WO2004098491A3 WO 2004098491 A3 WO2004098491 A3 WO 2004098491A3 US 0334523 W US0334523 W US 0334523W WO 2004098491 A3 WO2004098491 A3 WO 2004098491A3
Authority
WO
WIPO (PCT)
Prior art keywords
cpg oligonucleotides
preventing infections
immunostimulatory cpg
bioterrorism agents
bioterrorism
Prior art date
Application number
PCT/US2003/034523
Other languages
French (fr)
Other versions
WO2004098491A2 (en
Inventor
Dennis M Klinman
Bruce Ivins
Daniela Verthelyi
Original Assignee
Us Gov Health & Human Serv
Dennis M Klinman
Bruce Ivins
Daniela Verthelyi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Dennis M Klinman, Bruce Ivins, Daniela Verthelyi filed Critical Us Gov Health & Human Serv
Priority to US10/533,634 priority Critical patent/US7758876B2/en
Priority to EP03816929A priority patent/EP1572122A4/en
Priority to CA2504493A priority patent/CA2504493C/en
Priority to JP2004571713A priority patent/JP4976653B2/en
Priority to AU2003304107A priority patent/AU2003304107B2/en
Publication of WO2004098491A2 publication Critical patent/WO2004098491A2/en
Publication of WO2004098491A3 publication Critical patent/WO2004098491A3/en
Priority to AU2008203278A priority patent/AU2008203278B2/en
Priority to US12/786,326 priority patent/US8481055B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present disclosure relates to a method of preventing or treating an infection caused by a bioterrorism agent, specifically to a method of increasing an immune response to a bioterrorism agent using an oligodeoxynucleotide including a CpG motif, and a method of enhancing the immunogenicity of a vaccine against a bioterrorism agent using an oligodeoxynucleotide including a CpG motif.
PCT/US2003/034523 2002-11-01 2003-10-31 METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES WO2004098491A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US10/533,634 US7758876B2 (en) 2002-11-01 2003-10-31 Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
EP03816929A EP1572122A4 (en) 2002-11-01 2003-10-31 Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
CA2504493A CA2504493C (en) 2002-11-01 2003-10-31 Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
JP2004571713A JP4976653B2 (en) 2002-11-01 2003-10-31 Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides
AU2003304107A AU2003304107B2 (en) 2002-11-01 2003-10-31 Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
AU2008203278A AU2008203278B2 (en) 2002-11-01 2008-07-23 Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
US12/786,326 US8481055B2 (en) 2002-11-01 2010-05-24 Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42296402P 2002-11-01 2002-11-01
US60/422,964 2002-11-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10533634 A-371-Of-International 2003-10-31
US12/786,326 Division US8481055B2 (en) 2002-11-01 2010-05-24 Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides

Publications (2)

Publication Number Publication Date
WO2004098491A2 WO2004098491A2 (en) 2004-11-18
WO2004098491A3 true WO2004098491A3 (en) 2007-02-22

Family

ID=33434787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034523 WO2004098491A2 (en) 2002-11-01 2003-10-31 METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES

Country Status (6)

Country Link
US (2) US7758876B2 (en)
EP (1) EP1572122A4 (en)
JP (1) JP4976653B2 (en)
AU (2) AU2003304107B2 (en)
CA (1) CA2504493C (en)
WO (1) WO2004098491A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609108B2 (en) 2009-04-14 2013-12-17 The Secretary Of State For Defence Gamma-glutamyl transpeptidase attenuated Francisella
US8790910B2 (en) 2006-07-25 2014-07-29 The Secretary Of State For Defence Live vaccine strain
US8986685B2 (en) 1998-11-27 2015-03-24 Ucb Pharma S.A. Compositions and methods for increasing bone mineralization
US8992911B2 (en) 2003-06-16 2015-03-31 Ucb Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
US9296812B2 (en) 2005-05-03 2016-03-29 Amgen Inc. Sclerostin binding antibodies

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
IL139646A0 (en) * 1998-05-14 2002-02-10 Coley Pharm Group Inc Methods for regulating hematopoiesis using cpg-oligonucleotides
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1322655B1 (en) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
SI2241325T1 (en) * 2002-10-29 2012-05-31 Coley Pharm Group Inc Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7615539B2 (en) * 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
AU2005334819B2 (en) 2004-11-15 2011-11-24 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
WO2006065751A2 (en) 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
GB0519161D0 (en) * 2005-09-20 2005-10-26 Secr Defence Adjuvanted vaccine
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
SI2759306T1 (en) 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
CA2757620C (en) * 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
CN102946903B (en) 2010-05-14 2014-11-26 安进公司 High concentration antibody formulations
EP2739311B9 (en) 2011-08-04 2018-09-19 Amgen Inc. Method for treating bone gap defects
SG11201403718YA (en) 2011-12-28 2014-07-30 Amgen Inc Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
CN104619342A (en) 2012-07-05 2015-05-13 Ucb医药有限公司 Treatment for bone diseases
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
AU2019243595A1 (en) 2018-03-30 2020-09-17 Amgen Inc. C-terminal antibody variants
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
EP0580754A1 (en) 1991-04-18 1994-02-02 The Salk Institute For Biological Studies Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
ATE437943T1 (en) 1996-01-30 2009-08-15 Univ California EXPRESSION VECTORS THAT INDUCE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE AND METHODS FOR THEIR USE.
ES2241042T3 (en) * 1996-10-11 2005-10-16 The Regents Of The University Of California IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA.
US6214806B1 (en) * 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) * 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
EP1003850B1 (en) * 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
US6589940B1 (en) * 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
AU757175B2 (en) 1997-09-05 2003-02-06 Regents Of The University Of California, The Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
AU760549B2 (en) * 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
JP2002521489A (en) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Stereoisomers of CpG oligonucleotides and related methods
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
DK1832657T3 (en) * 1998-09-09 2012-12-17 Genzyme Corp Methylation of plasmid vectors
US20020065236A1 (en) * 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
EP1119375A4 (en) 1998-10-05 2005-02-02 Regetns Of The University Of C Methods and adjuvants for stimulating mucosal immunity
WO2000021556A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
CA2359636A1 (en) * 1999-01-22 2000-07-27 Andrew W. Taylor Activation of regulatory t cells by alpha-melanocyte stimulating hormone
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
WO2000062787A1 (en) 1999-04-15 2000-10-26 The Regents Of The University Of California Methods and compositions for use in potentiating antigen presentation by antigen presenting cells
WO2000067023A1 (en) 1999-04-29 2000-11-09 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
ES2250151T3 (en) 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. USE OF CPG AS A VACCINE ASSISTANT AGAINST HIV.
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
DE60041335D1 (en) 1999-08-19 2009-02-26 Dynavax Tech Corp METHOD FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOSTIMULATING SEQUENCES AND COMPOSITIONS THEREFOR
CN1454091A (en) * 1999-09-25 2003-11-05 衣阿华大学研究基金会 Immunostimulatory nucleic acids
WO2001022990A2 (en) 1999-09-27 2001-04-05 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
EP1322655B1 (en) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
AU4175101A (en) * 2000-02-23 2001-09-03 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
JP2003523398A (en) * 2000-02-24 2003-08-05 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Adjuvant therapy by in vivo activation of dendritic cells
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
EP1267618A1 (en) * 2000-03-28 2003-01-02 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
WO2003040308A2 (en) * 2001-07-27 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo
JP2005532067A (en) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド Nucleic acid composition for stimulating immune response

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KLINMAN D.: "CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine", EXPERT REV. VACCINES, vol. 5, no. 3, 2006, pages 365 - 369, XP008076241 *
KLINMAN ET AL.: "Use of CpG oligodeoxynucleotides as immune adjuvants", IMMUNOLOGICAL REVIEWS, vol. 199, 2004, pages 201 - 216, XP003008320 *
KRIEG A.: "CpG motifs in bacterial DNA and their immune effects", ANNU. REV. IMMUNOL., vol. 20, 2002, pages 709 - 760, XP009016455 *
See also references of EP1572122A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986685B2 (en) 1998-11-27 2015-03-24 Ucb Pharma S.A. Compositions and methods for increasing bone mineralization
US8992911B2 (en) 2003-06-16 2015-03-31 Ucb Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US9011856B2 (en) 2003-06-16 2015-04-21 Ucb Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US9296812B2 (en) 2005-05-03 2016-03-29 Amgen Inc. Sclerostin binding antibodies
US8790910B2 (en) 2006-07-25 2014-07-29 The Secretary Of State For Defence Live vaccine strain
US8609108B2 (en) 2009-04-14 2013-12-17 The Secretary Of State For Defence Gamma-glutamyl transpeptidase attenuated Francisella
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof

Also Published As

Publication number Publication date
US20100226941A1 (en) 2010-09-09
CA2504493A1 (en) 2004-11-18
AU2003304107A1 (en) 2004-11-26
AU2008203278A1 (en) 2008-08-14
AU2003304107B2 (en) 2008-05-15
CA2504493C (en) 2015-12-29
US7758876B2 (en) 2010-07-20
EP1572122A2 (en) 2005-09-14
AU2008203278B2 (en) 2010-09-02
WO2004098491A2 (en) 2004-11-18
EP1572122A4 (en) 2008-04-09
JP2006518337A (en) 2006-08-10
US20060019239A1 (en) 2006-01-26
US8481055B2 (en) 2013-07-09
JP4976653B2 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
WO2004098491A3 (en) METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
WO2004016805A3 (en) Immunostimulatory nucleic acids
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2004039829A3 (en) Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
WO2006091915A3 (en) Immunostimulatory oligonucleotides
ATE451119T1 (en) SUBUNITY VACCINE AGAINST RESPIRATORY SYNZYTIAL VIRUS
HK1104302A1 (en) Short interfering rna, short hairpin rna and coding vectors thereof, related compositions and use thereof used for inhibiting influenza virus infection
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
WO2001083503A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
WO2003028632A3 (en) Development of a preventive vaccine for filovirus infection in primates
WO2001012804A3 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
WO2002022675A3 (en) Plant genes, the expression of which are altered by pathogen infection
WO2001068116A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
PL398575A1 (en) Vaccine composition against West Nile virus infection
EP1829887A4 (en) Cpg single-strand deoxynucleotides for use as adjuvant
ITBO990602A0 (en) PROTECTION DEVICE FOR TRANSDUCERS, PARTICULARLY FOR HEMODIALYSIS PROCESSES.
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
WO2004045529A3 (en) West nile virus vaccine
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
WO2002087494A3 (en) Novel vaccine
WO2003051288A3 (en) Mycobacterial vaccine
WO2002045742A3 (en) Lipoteichoic acid immunogenic compositions and methods of making and using thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2006019239

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2504493

Country of ref document: CA

Ref document number: 10533634

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004571713

Country of ref document: JP

Ref document number: 2003304107

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003816929

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003816929

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10533634

Country of ref document: US